"The government has unveiled plans for a new £29.6 million RNA biofoundry in Darlington, designed to accelerate the development of next-generation therapies for cancer, dementia, cardiovascular disease and infectious illnesses. Backed by the Department for Science, Innovation and Technology (DSIT), the UK RNA Biofoundry will provide scientists and businesses with a dedicated, state-of-the-art facility to manufacture RNA materials at clinical grade and scale."
"RNA therapies - including the mRNA technology used to develop Covid-19 vaccines - are seen as one of the most transformative areas of modern medicine. Unlike traditional drugs, they can be designed quickly, adapted for multiple diseases, and offer much greater precision in how they target cells. Clinical trials in the NHS are already exploring their use in oncology and personalised immunotherapies."
""RNA therapies are a new frontier in healthcare," he said. "With their ability to reprogramme our cells and adapt to different diseases, they could be the answer to many treatments the British public are desperately in need of. This new biofoundry will accelerate the journey RNA therapies take from labs to the markets and give our innovators the best opportunities to turn their great ideas into lifesaving treatments.""
The UK will establish a £29.6 million RNA biofoundry in Darlington to accelerate development of next‑generation therapies for cancer, dementia, cardiovascular disease and infectious illnesses. The facility is backed by the Department for Science, Innovation and Technology and will provide state‑of‑the‑art manufacturing of clinical‑grade RNA materials for scientists and businesses, shortening the pathway from lab research to clinical trials and NHS deployment. RNA therapies can be designed rapidly, adapted across diseases, and target cells with high precision, but producing trial‑grade RNA is costly and complex. The biofoundry will offer affordable, rapid clinical‑standard production and can pivot to vaccine manufacture during pandemics.
Read at Business Matters
Unable to calculate read time
Collection
[
|
...
]